Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.7% | 1.5% | 7.0% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 7.0% | 19.0% | 39.8% | -40.2% | 23.9% | 42.6% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.7% | 1.5% | 7.0% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 7.0% | 19.0% | 39.8% | -40.2% | 23.9% | 42.6% |
Edgewood's large cap growth strategy delivered 1.48% net returns in Q4 2025 and 7.04% for the full year, underperforming benchmarks but generating strong fundamental results. The portfolio's 22 companies achieved 27% average EPS growth while stock returns averaged only 2%, creating significant stored alpha potential. Key contributors included Eli Lilly with 41% quarterly returns and Intuitive Surgical with 27% returns, while Netflix and ServiceNow detracted from performance. The firm added positions in Axon and Amphenol, both positioned for AI-driven growth opportunities. Axon's AI Era Plan represents the fastest product booking in company history, while Amphenol benefits from higher interconnect content in AI servers. Portfolio risk controls include sector diversification limits and position sizing constraints. Management maintains confidence in the quality growth strategy, noting that internal team members made substantial investments in Q3 2025, and expects stored alpha to drive future outperformance as market leadership broadens beyond current AI infrastructure concentration.
Edgewood focuses on high-quality large cap growth companies with durable competitive advantages, strong cash flow generation, and market-leading positions across AI infrastructure, healthcare innovation, enterprise software, and financial services.
Management remains confident in portfolio fundamentals despite 2025 underperformance. Portfolio companies delivered 27% average EPS growth versus 2% stock performance, creating stored alpha opportunity. Expects earnings strength to continue in 2026 with potential for performance as market leadership broadens beyond AI infrastructure names.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Dec 31 2025 | 2025 Q4 | ASML, AVGO, AXON, BSX, BX, FICO, INTU, ISRG, LLY, MSCI, NFLX, NOW, NVDA, SHOP, SNPS, SPGI, SPOT, TDG, V, VRTX | AI, growth, healthcare, large cap, Quality, semiconductors, software, technology |
AXON APH |
AI infrastructure buildout driving strong demand for semiconductors and data center components. AI Era Plan from Axon represents fastest booked product to date, with Draft… |
| Sep 30 2025 | 2025 Q3 | ASML, BSX, FICO, ISRG, LLY, SNPS | Artificial Intelligence, earnings growth, Large Cap Growth, risk management, Semiconductor Equipment |
FICO LLY ASML SNPS ISRG BSX |
The presentation emphasizes a concentrated 22-stock large cap growth portfolio with roughly 28% exposure to AI infrastructure buildout, supported by disciplined risk controls including an… |
| Jun 30 2025 | 2025 Q2 | AVGO, BSX, FICO | Artificial Intelligence, earnings growth, Large Cap Growth, Portfolio Concentration, Stored Alpha |
AVGO FICO |
The Q4 2025 update underscores a concentrated 22-stock large-cap growth portfolio with disciplined risk controls, including 28% position sizing and a 25% sector cap, designed… |
| Mar 31 2025 | 2025 Q1 | SHOP, SPOT | Balance Sheet Strength, free cash flow, Large Cap Equities, Market Share Gains, secular growth |
SHOP SPOT |
The letter emphasizes durable large-cap growth franchises with strong free cash flow generation and secular revenue drivers, arguing that quality compounders can navigate macro volatility… |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
SemiconductorsRGA initiated a position in Lattice Semiconductor, viewing it as an under-appreciated AI winner with immediate gains and longer-term optionality. Lattice's focus on efficiency and advantages in low-power, small footprint FPGAs position it favorably for AI servers, particularly as the only Post-Quantum Cryptography secure chips on the market. |
FPGAs Security Efficiency AI Infrastructure Programmable | |
Software |
||
| 2025 Q3 |
Growth |
|
| 2025 Q2 |
Growth |
|
| 2025 Q1 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Fund Letters | Alan Breed | APH | Amphenol Corporation | Information Technology | Electronic Components | Bull | New York Stock Exchange | Acquisitions, Aerospace, Artificial Intelligence, Automation, Connectors, data centers, Defense, semiconductors | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | FICO | Fair Isaac Corporation | Information Technology | Application Software | Bull | New York Stock Exchange | analytics, credit scoring, market share, Mortgage, Pricing power, recurring revenue, Regulation | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | LLY | Eli Lilly and Company | Health Care | Pharmaceuticals | Bull | New York Stock Exchange | Clinical trials, Diabetes, drug pipeline, earnings growth, GLP-1, Obesity, valuation | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | ASML | ASML Holding N.V. | Information Technology | Semiconductor Materials & Equipment | Bull | New York Stock Exchange | Artificial Intelligence, Capital equipment, Euv, Lithography, market share, secular growth, semiconductors | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | SNPS | Synopsys, Inc. | Information Technology | Application Software | Bull | NASDAQ | Artificial Intelligence, backlog, Eda, Export restrictions, Intellectual Property, recurring revenue, Semiconductor Design | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | ISRG | Intuitive Surgical, Inc. | Health Care | Health Care Equipment | Bull | NASDAQ | Installed base, Margins, Medical devices, Procedure Growth, recurring revenue, robotics, Surgical Systems | Login |
| Sep 30, 2025 | Fund Letters | Alan Breed | BSX | Boston Scientific Corporation | Health Care | Health Care Equipment | Bull | New York Stock Exchange | Afib, capital deployment, Electrophysiology, Margins, Medical devices, organic growth, pipeline | Login |
| Jun 30, 2025 | Fund Letters | Alan Breed | AVGO | Broadcom Inc. | Information Technology | Semiconductors | Bull | NASDAQ | AI infrastructure, capital return, custom silicon, Free Cash Flow, hyperscalers, Software | Login |
| Jun 30, 2025 | Fund Letters | Alan Breed | FICO | Fair Isaac Corporation | Information Technology | Application Software | Bull | New York Stock Exchange | buybacks, credit scoring, Mortgage Volumes, network effects, Pricing power, Regulatory risk | Login |
| Mar 31, 2025 | Fund Letters | Alan Breed | SHOP | Shopify Inc. | Information Technology | Internet & Direct Marketing Retail | Bull | New York Stock Exchange | B2b, e-commerce, Free Cash Flow, Gross margin, international expansion, Payments, platform, POS | Login |
| Mar 31, 2025 | Fund Letters | Alan Breed | SPOT | Spotify Technology S.A. | Communication Services | Interactive Media & Services | Bull | New York Stock Exchange | advertising, Free Cash Flow, Gross margin, monetization, Personalization, Podcasts, Streaming, Subscriptions | Login |
| Dec 31, 2025 | Fund Letters | Alan Breed | AXON | Axon Enterprise, Inc. | Industrials | Aerospace & Defense | Bull | NASDAQ | Artificial Intelligence, international expansion, Keyence, Margins, Public safety, recurring revenue, SaaS, Subscriptions | Login |
| TICKER | COMMENTARY |
|---|---|
| ASML | ASML, TSMC, and Arista Networks are key players in the AI build out supply chain. |
| AVGO | The primary contributors to its performance were our exposures to Broadcom |
| AXON | Axon Enterprise Inc. develops and produces Taser weapons and body cameras for law enforcement agencies. Investors have grown accustomed to big beats and raises from Axon. A slight beat to third-quarter projections and mixed fourth-quarter guidance triggered a -21% decline. We added to the position due to solid customer growth and retention. There are also numerous growth drivers for their business including Taser 10, bodycam 4, and their artificial intelligence software bundle. |
| BSX | However, Boston Scientific has fallen sharply following an earnings report on February 4 that missed expectations. |
| BX | Blackstone declined. The world's leading alternative asset managers, such as Blackstone, also declined in 2025. We also right-sized our positions in Blackstone – both of which remain in Montaka's top 10. |
| FICO | Fair Isaac Corporation (FICO), a data and analytics company focused on predicting consumer behavior, contributed to performance. FICO reported strong quarterly financial results and solid fiscal 2026 guidance, which calls for 28% EPS growth. The company also launched its new Direct Licensing Program for mortgage lending, which provides greater flexibility to monetize its intellectual property. |
| INTU | ServiceNow (NOW) and Intuit (INTU) exemplify this dynamic, advancing meaningful AI initiatives that enhance customer value and deepen competitive advantages. Intuit is deploying intelligent agents and conversational tools like 'Ask Anything' to simplify complex financial tasks across QuickBooks and TurboTax. |
| ISRG | ISRG shares appreciated in the fourth quarter after the company delivered strong Q3 results highlighting continued procedure growth and accelerating system placements. Procedure volumes rose in the mid-teens globally, with notable strength in general surgery and urology, while recurring instrument and accessory revenue grew faster than expectations. Management also reported that the early rollout of its next-generation robotic platform was tracking ahead of schedule, with utilization metrics trending positively across beta sites. |
| LLY | Eli Lilly shares were a top performer in 4Q25 after delivering strong Q3 2025 earnings in October. Revenue rose 54% year-over-year to $17.6 billion, and adjusted EPS of $7.02 beat consensus of $6.02. Growth was driven by its GLP-1 franchises, Mounjaro and Zepbound, where sales more than doubled year-over-year, alongside strength in other therapeutic areas. Management raised full-year guidance for both revenue and earnings, reinforcing investor confidence in the company's growth outlook. |
| MSCI | MSCI Inc. 4.3 1.40 (0.02) |
| NFLX | NFLX was the portfolio's largest detractor in 4Q25 following investor concerns around near-term subscriber growth and rising content spending. While revenue grew approximately 10% year-over-year, management guided to slower net subscriber additions in North America and Europe after recent price increases, and margins were pressured by elevated investment in live sports and international content. |
| NOW | In the case of ServiceNow, the stock weakened following reports of a potential large acquisition while the company has also been challenged by bearish sentiment across the software as a service or SAAS segment. |
| NVDA | AI bellwether NVIDIA's very strong set of earnings in late November helped the AI theme re-assert its dominance when investors breathed a sigh of relief following the results. |
| SHOP | Shopify Inc. is a cloud-based software provider for multi-channel commerce. Shares rose 8.3% in the fourth quarter, finishing 2025 up 51.1% on strong financial results that outperformed Street expectations. The company is demonstrating rapid growth at scale with gross merchandise value (GMV) and revenues each growing over 30% year-on-year. |
| SNPS | Key performance contributors in the month of December included AppLovin, Synopsys, and PAR Technology Corporation. |
| SPGI | Leading rating agency and data provider S&P Global Inc. contributed to performance. Shares rebounded from a pullback in September that stemmed from a competitor's cautious commentary around market demand and margins. S&P Global alleviated these concerns by delivering strong third quarter results and raising its full-year financial guidance. |
| SPOT | Spotify is the world's leading audio streaming platform. Third-quarter results showed continued operating progress, with users increasing 11% to 713 million and subscribers growing 12% to 281 million. Meanwhile, operating income expanded to a mid-teens margin, alongside a record quarterly free cash flow. Despite the momentum, the shares weakened as investors reset near-term margin expectations. Spotify has been a top contributor to long-term Fund performance, and we remain confident that pricing, product innovation, advertising efficiency, and an expanding ecosystem can continue to widen margins over time, as reinforced this quarter by the launch of Spotify recommendations within ChatGPT. |
| TDG | TransDigm is a leading aerospace parts supplier that designs and produces highly engineered components for almost every commercial and military aircraft in service today. TransDigm has spent the last 30 years building a portfolio of hundreds of thousands of parts with these characteristics. And while each part breaks unpredictably and infrequently, by assembling this vast portfolio, they have essentially created a collection of near monopolies that create an incredibly smooth and high pricing power annuity stream. |
| V | There were companies there such as Visa, which we own, as well as many we do not, and which would not likely be appropriate for this mandate. |
| VRTX | Top gainers in the Fund this quarter included Vertex Pharmaceuticals (+16%) |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||